Across all 3 studies in the database, Bacopa showed beneficial effects on improved attention span, with 2 studies reporting small effect sizes and 1 reporting a moderate effect. The only study reporting a dose used 160 mg/day, and effects were observed in a clinical population with mild cognitive impairment at a median duration of 60 days. The evidence base is very small, so findings should be considered preliminary.
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed).
Bacopa monnieri consistently improved inattention, hyperactivity, and memory
While in the field of attention at the end of the first month (P = 0.033) and the end of the second month (P = 0.004), it was significant difference between the study groups.
BM can reduce Nuclear Factor-κB phosphorylation, improve emotional function, cognitive functions, anhedonia, hyperactivity, sleep routine, depression, attention deficit, learning problems, memory retention, impulsivity, and psychiatric problems.